Monique McHenry, PhD
Monique McHenry, PhD is a botanist with a background in plant diversity and evolution. She is the director of the Medical Cannabis Center for Research and Education and co-director of the cannabis pharmacology course at the University of Vermont Medical School. She is also Co-Founder of the CASE Institute, a plant-based pharmaceutical research enterprise. Dr. McHenry completed her BA and MSc at the University of Colorado, and her PhD at the University of Vermont.
Kalev Freeman, MD, PhD
Kalev Freeman, MD, PhD is a physician-scientist with a background in molecular biology and specific research interest in inflammation and injury. He is co-founder of the CASE Institute, a plant-based pharmaceutical research enterprise. He completed his BA at the University of Michigan, and both his MD and PhD at the University of Colorado, where he specialized in molecular biology.
Karen Lounsbury, PhD
Karen Lounsbury, PhD is a professor of pharmacology at the University of Vermont College of Medicine. Research in Dr. Lounsbury’s laboratory is focused on understanding mechanisms whereby signals generated at the plasma membrane are communicated to the nucleus of vascular cells to mediate vascular remodeling and angiogenesis. Signaling pathways of current interest include protein kinase cascades, hypoxia signaling and mechanisms of calcium-regulated gene transcription in arterial smooth muscle cells and ovarian tumor cells.
William Cats-Baril, PhD
William Cats-Baril, PhD is as an Associate Professor for Information and Decision Sciences in the Grossman School of Business. Dr. Cats-Baril has worked closely with the medical community, in particular the orthopedic and plastic surgery communities, for the last 25 years. He was a Principal Investigator in the Vermont Rehabilitation Engineering Center (VREC) where he developed a predictive risk model of low back pain disability. His current research interests include the design of integrated health care delivery systems, the prevention of suicide, and strategies to address the opiate crisis.
Wolfgang Dostmann, PhD
Wolfgang Dostmann, PhD is a professor of pharmacology at the University of Vermont College of Medicine, and teaches a course on cannabis pharmacology. His research interests focus on the topic of second messenger signaling, and he and his team specialize in research on the contraction function of muscle cells in blood vessels. Dr. Dostmann’s research is stimulated by and integrated through the use of a large variety of methods and techniques ranging from organic chemistry, biochemistry, molecular biology, cell biology, biophysics, physiology and pharmacology.
Frances Carr, PhD
University of Vermont Professor, Department of Pharmacology
John MacKay, PhD
Waters Technologies - Senior Director, Strategic Technologies
John MacKay, PhD is Associate Professor for UVM’s Department of Pharmacology, Chief Technology Officer for NewBridge Global Ventures, and Founder of Synergistic Technologies Associates. His research is focused on analytical testing, extraction techniques, and purification techniques related to medical cannabis. Dr. MacKay earned a B.A. in Chemistry from St. Lawrence University and a Ph.D. from the University of Vermont in Inorganic Chemistry.
John McPartland, DO, MS
University of Vermont College of Medicine, Family Medicine Department
John McPartland, DO, MS works for the UVM Department of Family Medicine. Beginning cannabinoid research in 1981, Dr. MacPartland has researched the history and evolution of the cannabis plant, synergistic action of cannabis compounds, and therapeutic uses of medical cannabis. He received his BS in Botany and Chemistry from Penn State, his MS in Plant Pathology from University of Illinois, and his Doctor of Osteopathy from Chicago College of Osteopathic Medicine.